Radiopharm Theranostics Limited (RADX)

Market Cap	32.40M
Revenue (ttm)	204,609
Net Income (ttm)	-26.61M
Shares Out	2.20B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,022
Open	4.000
Previous Close	4.050
Day's Range	3.990 - 4.000
52-Week Range	3.496 - 50.820
Beta	0.80
Analysts	Strong Buy
Price Target	13.50 (+238.35%)
Earnings Date	Feb 26, 2025

About RADX

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: RADX

Financial Performance

In 2024, Radiopharm Theranostics's revenue was 1.96 million, a decrease of -68.46% compared to the previous year's 6.21 million. Losses were -47.95 million, 38.5% more than in 2023.

Financial numbers in AUD

Analyst Summary

According to 2 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 238.35% from the latest price.

Price Target

$13.5

(238.35% upside)

Analyst Consensus: Strong Buy